Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

APOLLO: A Phase 3 Multicenter, Multinational, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Patisiran (ALN-TTR02) in Transthyretin (TTR)-Mediated Polyneuropathy (Familial Amyloidotic Polyneuropathy-FAP)

Next Previous
Trial Profile

APOLLO: A Phase 3 Multicenter, Multinational, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Patisiran (ALN-TTR02) in Transthyretin (TTR)-Mediated Polyneuropathy (Familial Amyloidotic Polyneuropathy-FAP)

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 27 Sep 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Patisiran (Primary)
  • Indications Amyloid polyneuropathy; Familial amyloid neuropathy; Transthyretin-related hereditary amyloidosis
  • Focus Registrational; Therapeutic Use
  • Acronyms APOLLO
  • Sponsors Alnylam Pharmaceuticals

Most Recent Events

  • 01 Sep 2024 Results (n=18) the sub analysis examining the efficacy and safety of patisiran, in Taiwanese patients with hereditary transthyretin-mediated (hATTR) amyloidosis with polyneuropathy were published in the Journal of the Formosan Medical Association.
  • 24 Jan 2023 Results assessing effect of patisiran on stroke volume in hereditary transthyretin-mediated amyloidosis, published in the European Journal of Heart Failure.
  • 29 Aug 2022 Results of pooled analysis assessing quantitative effect of patisiran and vutrisiran on orthostatic hypotension in patients with hATTR amyloidosis with polyneuropathy presented at the ESC Congress 2022 - Annual Congress of the European Society of Cardiology

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top